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INTRODUCTION 
Hypertensive disorders during pregnancy are among the commonest medical 
disorders during pregnancy and continue to be the most important cause of 
maternal and perinatal mortality and morbidity worldwide. Hypertensive disorders 
complicate 5-10% of all pregnancies with hypertension, Pre-eclampsia syndrome 
either alone or superimposed on chronic hypertension is the most dangerous. 
Pre-eclampsia complicates 3-8% of pregnancies (James high-risk pregnancies 7
th
 
edition) major cause of maternal mortality and prenatal death and premature birth.  
Onset of preeclampsia occurs after 20 weeks of gestation. Incidence is markedly 
influenced by race and ethnicity (Genetic predisposition) other factors include 
environmental, socioeconomic and even seasonal influences. The incidence of pre-
eclampsia in Nulliparous population ranges from 3-10% (Sibai& Cunningham 
2009).  
To reduce the impact of pre-eclampsia on maternal mortality, it is necessary to 
establish correct diagnosis of pre-eclampsia and to proceed with early interventions 
to prevent complications. In the past few decades, several methods have been 
developed to establish the disease as early as possible, many of these tests could 
not be used as screening test, due to their false positive results and subjective 
11 
 
interpretation. Hence, there is a need for the screening test to predict pre-eclampsis 
at the early period of gestation. 
Renal function changes may be seen in women preeclampsia, without any 
symptoms. Several studies have shown that hypocalciuria is associated with 
preeclampsia. Rodriquez et al in his study has shown that decreasing calcium-
creatinine ratio and micro-albuminuria may be used to predict pre-eclampsia and 
concluded that it may be used as a screening tools. 
The purpose of this study is to find out the predictive values of urinary calcium to 
creatinine ratio and micro-albuminuria in all asymptomatic pregnant women and 
recommend it as a screening test for pre-eclampsia. 
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REVIEW OF LITERATURE 
 
1. Eclampsia was first noted in the Hippocrates writings (430-330BC) 
2. De-La Motte (1726) considered oedema to be benign unless associated with 
convulsions. 
3. DESAVEREGES (1739) wrote, “All convulsions of acute causation 
iseclampsia”. 
4. VOGEL (1764) & GILLEN (1771) formed “Eclampsiaparturientum” 
5. Zweifel and Chesley described Preeclampsia as disease of theories. 
6. Zweifel first termed pre-eclampsia as “Toxemia”.  
7. Bossier (1790) first introduced term eclampsia. 
8. Frerichs (1851) published Eclampsia as a form of Uremia. 
9. LAHLEIN 1918, FAHR 1920 → described changes in Glomeruli.  
10. Farguhar (1959) → demonstrated glomerular capillary endotheliosis by 
electron microscopy. 
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11. In 1991, Redmann regarded pre-eclampsia as inadequate response of mother   
to the presence of conceptus.  
12. In 1994, Gill postulated that pre-eclampsia occurs in families and suggested 
a Recessive Mendelian Trait. 
13. Tweedy Duslinstrangnoff in Russia – Conservative expectant management  
with sedation and Anti-hypertensive, in hope of reducing neonatal mortality  
occurring due to premature termination. 
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Definition 
According to NHBEP & ACOG (2002), Hypertension in pregnancy is defined 
as, 
 Systolic BP greater than or equal to 140 mm Hg  and /or  
 Diastolic BP greater than or equal to 90 mm Hg (Korotkoff 5) after 20 
weeks of gestation in a woman previously with normal BP (NHBEP 2000 
ACOG 2002)  
These measurements should be confirmed by repeated readings over 4-6hours. 
Where K5 is absent, K4 (muffling) should be accepted. 
 
Severe hypertension in pregnancy is defined as, 
 Systolic BP greater than or equal to 160 mm Hg and / or. 
 Diastolic BP greater than or equal to110mm Hg.  
 
This BP level represents, the level at which cerebral auto regulation is overcome. 
Systolic hypertension as well as Diastolic hypertension increases the risk of 
cerebral hemorrhage. 
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Blood pressure measurement  
1. Conventional sphygmomanometer is suitable for routine use. 
2. Woman should be relaxed and resting for at least half an hour before blood 
pressure measurement. 
3. BP measurement should be done in sitting position with right forearm 
horizontal and well supported and the upper arm at the level of heart. (Left 
atrium)  
4. The cuff should be long enough to encircle the arm and wide enough to 
cover at least two thirds of upper arm. It should be firmly applied, and 
inflated and deflated smoothly. 
5. The disappearance of Korotkoff sounds (K5) has been shown to correlate 
better with direct intra-arterial measurements of Diastolic pressure. Hence it 
is recommended that K5 should be routinely used in pregnancy. 
 
Classification 
Various schemes of classifying hypertensive disorders in pregnancy have been 
proposed by different obstetric and hypertension societies. A recent classification 
recommended by the National Institute of Health (NIH) working group on high 
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Blood Pressure in Pregnancy 2000 – NH BP EP 2000 has categorized hypertensive 
disorders into 4 types. 
1. Gestational hypertension – formerly termed pregnancy induced 
hypertension. If pre-eclampsia does not develop and hypertension resolves 
by 12 weeks postpartum, it is re designated as transient hypertension. 
2. Pre-eclampsia and eclampsia syndrome 
3. Pre-eclampsia syndrome superimposed on chronic hypertension 
4. Chronic hypertension 
 
The classification adopted by International Society for the Study of Hypertension 
in pregnancy (ISSHP) reflecting both the pathophysiology of the condition and the 
risks and potential outcomes for both mother and baby is  
1. Gestational hypertension 
2. Pre-eclampsia 
 
3. Chronic hypertension         
 
4. Pre-eclampsia superimposed on chronic hypertension 
 
Essential 
Secondary 
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DIAGNOSIS OF HYPERTENSIVE DISORDERS IN PREGNANCY 
 
 
GESTATIONAL HYPERTENSION 
BP >140/90 mm Hg ,first time during pregnancy 
No proteinuria 
BP becomes normal before 12wks postpartum 
Final diagnosis made only in postpartum 
 
 
 
 
 
              PREECLAMPSIA 
Minimum criteria: 
BP >140/90 mm Hg after 20 wks 
Proteinuria >300mg/24hrs or >1+dipstic 
Increased certainty of preeclampsia: 
BP > 160/110 mmHg 
Proteinuria 2g/24hrs or >2+ dipstic 
Serum creatinine>1.2 mg/dl 
Platelets <100,000 / µl 
Microangiopathic hemolysis-increased LDH 
Elevated serum transaminase levels-ALT /AST 
Persistent headache or other cerebral or visual 
disturbance 
Persistent epigastric pain 
              ECLAMPSIA Seizures which cannot be attributed to any other 
cause in a woman with preeclampsia 
 
SUPERIMPOSED  
PREECLAMPSIA ON CHRONIC 
HYPERTENSION 
New onset proteinuria > 300mg/24hrs before 20 
weeks in a hypertensive woman. 
Sudden rise in proteinuria or BP or platelet count 
<100,000/ µl before 20 weeks in a women with 
hypertension and proteinuria 
 
CHRONIC HYPERTENSION 
BP >140/90 mmHg before pregnancy or diagnosed 
before 20 weeks, not attributable to gestational 
trophoblastic disease      OR 
Hypertension diagnosed first after 20 wks  and  
persistent after 12 wks postpartum  
19 
 
RISK FACTERS 
Couple- Related Risk Factors. 
 Primi-paternity. 
 Limited sperm exposure. 
 Pregnancies after donor insemination, oocyte donation, embryo donation.  
 Protective effect of “Partner change” in case of previous pre-eclamptic 
pregnancy. 
 Dangerous male partner (Paternal effects).  
 
Maternal or Pregnancy – related risk factors. 
 Age:  Extremes of maternal age. (< 20years and > 35years). 
 Multi-fetal Gestation. 
 Pre-eclampsia in a previous pregnancy. 
 Chronic hypertension and / or renal disease. 
 Maternal chronic inflammatory conditions  
(Eg: Rheumatologic disease, SLE). 
 Maternal chronic infections. 
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 Maternal low birth weight. 
 Obesity and insulin resistance (with or without the polycystic ovary 
syndrome, this risk is proportionate to BMI). 
 Pre-gestational Diabetes mellitus. 
 Pre-existing thrombophilias. 
 Maternal susceptibility genes. 
 Family history of pre-eclampsia. 
 Smoking (reduced risk). 
 Hydropic degeneration of the placenta. 
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ETIOPATHOGENESIS 
The exact actiolagy of pre-eclampsir remains unknown.  
As Boyd stated Pre-eclampsia remains “die krankheit der theorien”- the disease of 
theories. 
Etiology:- 
1. Placental implantation with abnormal trophoblastic invasion of 
uterine vessels. 
2. Inappropriate endothelial cell activation. 
3.  Immunologic maladaptive tolerance between maternal, paternal 
(placental) and fetal tissues. 
4. Maternal maladaptation to cardiovascular or inflammatory changes of 
normal pregnancy. 
5. Exaggerated inflammatory responses. 
6. Increased vasopressor response & vasospasm. 
7. Genetic factors including inherited predisposing genes and epigenetic 
influences. 
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TWO STAGES OF PRE-ECLAMPSIA 
(Borzychowski 2006 & Redman 2009) 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Stage -1 
First half of 
pregnancy 
Stage -2 
Second half 
of pregnancy 
Poor placentation 
Placental oxidative 
Stress & Inflammation 
Systemic release of 
placental factors 
like SFLT-1 and 
other 
syncytiotrophoblast 
derived factors 
Maternal systemic 
inflammatory 
response, 
endothelial 
activation  
Pre-eclampsia 
syndrome  
Fetal Growth restriction 
 
 
No 
Symptoms 
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Two basic abnormalities seen in pathophysiology of pre-eclampsia are  
1. Abnormal placentation. 
2.  Endothelial dysfunction.  
Abnormal Tophoplastic Invasion. 
 
In normal pregnancies, endovascular cytotrophoblasts replace endothelial cells in 
spiral arteries, this leads to destruction of the medial elastic, muscular and neural 
tissue. These physiologic changes normally reach the inner third of myometrium. 
These changes results in an arteriolar system with decreased resistance and without 
maternal vasomotor control, this allows increased blood supply to the fetus. The 
end result of these changes is that 100-120 spiral arteries are remodeled by the 
invading “foreign” CTBs into dilated, inelastic tubes without maternal vasomotor 
control. This process starts around 10-12 weeks and is completed by 18-20 weeks. 
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In pre-eclampsia, physiologic changes in many but not all spiral arteries are 
confirmed to decidual portion. The myometrial segments in these arteries remain 
anatomically intact, which does not dilate and retains its adrenergic nerve supply. 
The inner myometrial arterioles retains its endothelial lining and musculoelastic 
tissues, with mean external diameter half of that of vessels in normal placentas 
(Fishes & Colleagues 2009). 
Magnitude of defective trophoblastic invasion of the spiral arteries correlates with 
severity of hypertensive disorder (Madazli& associates 2000). 
Initially lipids get accumulated in myointimal cells and then within macrophages. 
Such findings were referred to as atherosis (Hertig 1945). 
The abnormal spiral arteriolar lumen leads to decreased placental blood flow with 
a hypoxic environment, which causes the release of placental debris that incites a 
systemic inflammatory response as described by Redman & Sargent (2008). 
 
Endothelial cell activation:- 
Endothelial activation is a part of the generalized inflammatory reactions involving 
leucocytes as well as clotting and complement systems. Endothelial cell 
dysfunction is due to an extreme activated state of leucocytes in maternal 
circulation (Fars 2000, Gervasi 200, Redman 1999). 
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Renin-Angiotensin system is not stimulated, despite relative hypovolemia in severe 
pre-eclampsia, increased vascular sensitivity to vasoconstrictors and increased 
endothelial cell permeability can be explained in the basis of endothelial cell 
activation. 
Selective platelet activation and consumption (microangiopathic hemolysis) and 
the resulting reduction in placental blood flow due to spiral artery Thrombosis & 
placental infarction can be attributed to endothelial cell dysfunction. Cytokines 
contributes to oxidative stress associated to pre eclampsia. 
Reactive oxygen species and free radicals lead to formation of self-propagating 
lipid peroxides (Manten& associates 2000) which generate highly Toxic radicals, 
which will injure endothelial cells and modify nitric oxide production and interfere 
with prostaglandin balance, which promote coagulation and increased sensitivity to 
vasopressor agents.  
Immunological Factors:- 
Loss of maternal immune tolerance to paternally derived placental and fetal 
antigens is cited to account for pre-eclampsia syndrome. 
Histological changes at the maternal placental interface are suggestive of acute 
graft rejection (Labarrere 1988). 
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The risk of pre-eclampsia is increased in circumstances where formation of 
blocking antibodies to placental antigenic sites might be impaired – first pregnancy 
would carry a higher risk. 
“Tolerance dysregulation” also explains an increased risk when paternal antigenic 
load is increased (as with 2 sets of paternal chromosomes). Belo Lah& associates 
(2006) showed that these women have elevated levels of antiangiogenic factors 
(SFLTI). 
In women likely to become pre-eclampsia, early in gestation, the extra villous 
trophoblast express reduced amounts of immunosuppressive human leucocytes 
antigen G (HLA G) which contributes to defective placental vascularisation. 
In  normal pregnancy, T helper (Th) lymphocytes  produced, increases type 2 
activity  relation to type 1 termed type 2 bias (Redman & Sargent 2008). 
Th-2 cells promote humoral immunity; Th-1 cells stimulate cytokine secretion. In 
pre-eclampsia, at the beginning of second trimester, the Th-1 action is increased 
and the ratio Th-1 / Th-2 changes. Immunologically mediator inflammatory 
reactions are stimulated by placental micro particles as well as by adiposities 
(Redman & Sargent 2008). 
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Genetic Factors:- 
Pre-eclampsia is a multifactorial, polygenic disorder (Ward & Lindheimer-2009). 
It is also reported that, risk of pre-eclampsia is 20-40% for daughters of pre-
eclamptic mothers, 11-37% for sisters of pre-eclamptic women and 22-47% for 
twin babies. 
Vasospasm:- 
Vascular constriction causes increased resistance and subsequent hypertension 
with decreased blood flow due to mal-distribution and ischemia of surrounding 
tissues leading to necrosis, hemorrhage and other end organ disturbance 
characteristic of the syndrome. 
Increased Pressure Responses:- 
Increased sensitivity to angiotension II clearly precedes the onset of Gestational 
hypertension. Grant & Colleagues (1974) showed that normotensive nulliparas 
remained refractory to infused angiotensin II, but those who subsequently became 
hypertensive lost this refractoriness several weeks before the onset of hypertension. 
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Prostaglandins:- 
 In normal pregnancy, endothelial prostaglandins mediate decreased vascular 
response to presser agents. 
 Endothelial prostaglandins (PGI2) production is decreased in pre-eclampsia. 
This action appears to be mediated by phospholipase A2 (Taylor and Roberts 
1999). 
 At the same time, thromboxane A2 secretion by platelets increased and the 
Prostacyclin: Thromboxane A2 ratio decreases. The net result favours 
increased sensitivity to infused angiotensin II & Vasoconstriction (Spitz and 
colleagues 1988). These changes are apparent as early as 22 weeks in 
women who later develop pre-eclampsia (Chavarria& Co-workers 2003). 
Nitric Oxide:- 
 Synthesised in endothelial cells from L-arginine. It is a potent vasodilator. 
Inhibition of NO synthesis increases mean arterial pressure, decreases heart 
rate and reverses the pregnancy induced refractoriness to Vasopressors. 
 Low-pressure vasodilated state characteristic of fetoplacental perfusion is 
maintained by nitric oxide (Myatt & Co-worker 1992, Weiner and associates 
1992). NO also synthesized from fetal endothelium and is increased in 
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response to pre-eclampsia, diabetes and infection (Parra & associates 2001, 
Von Mondach& Co-workers 2003). 
 In pre-eclampsia, these is decreased NO synthase expression & increasing 
NO inactivation. 
Endothelins:- 
 These are potent Vasoconstrictors, Endothelin 1 (ET-1) is primary isoform 
produced by endothelium (Mastrogiannis& Co-workers 1991). 
 Plasma ET 1 levels are increased in normotensive pregnant woman, woman 
pre-eclampsia have even high levels. (Ajne 2003, Clark 1992, Nova 1991). 
 Placenta is not the only source of increased ET-1 concentrations and they 
likely arise from systemic endothelial activation (Taylor and Roberts 1991) 
 Treatment of pre-eclampsia woman with magnesium sulphate lowers ET-1 
concentrations (Sagsoz and Kucukozkan 2003) 
Angiogenic and Antiangiogenic Proteins:- 
 Vascular endothelial growth factors and angiopoeitins (Ang) gene products 
are extensively studied in placental vascular development. 
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 Excessive amounts of antiangiogenic factors are thought to be stimulated by 
the worsening hypoxic environment at the uteroplacental interface leading to 
imbalance in angiogenesis. 
 Trophoblastic tissue of women who will develop pre-eclampsia 
overproduces at least two antiangiogenic peptides that enter maternal 
circulation (Karumanchi and Colleagues 2009). 
a. Soluble Fms like Tyrosine Kinase (SFlT-1) is a variant of flt-1 
receptor for placental growth factor (PlGF) and vascular 
endothelial growth factor (VEGF). Increased SFlt-1 levels may 
inactivate and decrease circulating PlGF and VEGF concentrations 
causing endothelial dysfunction (Maynard and associates 2003). 
 
b. Soluble endoglin (S Eng) is a placenta-derived molecule that 
blocks endoglin also called CD 105, which is a co-receptor for 
TGF β family. 
 This soluble form of endoglin inhibits TGF β isotopes from binding to 
endothelial receptors and results in decreased endothelial Nitric oxide 
dependent vasodilatation (Levine and Co-workers 2006, Venkatesha& 
associates 2006). 
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 The soluble forms are not increased in the fetal circulation or amniotic fluid 
and their levels dissipate after delivery (Staff & Co-workers 2009). 
 Research currently focused an immunological mechanisms, oxidative stress, 
mitochondrial pathology and hypoxic genes (Karumanchi& Colleagues 
2009). 
 Widner and associates (2007) concluded that retrospective studies showed 
third trimester elevation of sflt 1 levels and decreased PlGF concentration 
correlates with development of preeclampsia after 25 weeks. 
Nutritional Factors:- 
 Diet rich in fruits and vegetables that have anti-oxidant activity is associated 
with decreased blood pressures (John & Co-workers 2002).  
 Daily intake of ascorbic acid less than 85mg was associated with increased 
incidence of preeclampsia (Zhang and associates 2002). 
 Calcium supplementation in population with low calcium intake had a small 
effect to lower perinatal mortality rates (Villar and associates 2006). 
 
 
32 
 
ETIOPATHOGENESIS 
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Pathophysiology 
The cause of pre-eclampsia remains unknown and evidence for its manifestation 
begins early in pregnancy.  
Abnormal placentation is thought to be the initial events. Some of the main 
features include improper trophoblastic invasion of spiral arterioles and accelerated 
apoptosis of the trophoblasts with abundant release of fetal DNA into maternal 
circulation. This leads to decreased perfusion of uteroplacental vessels. The 
disruption of normal placentation may to lead to synthesis of products, which 
affect angiogenesis, and to abnormal lipid peroxidation. 
With advance in gestation, these products will affect the endothelial system with 
production of signs and symptoms of multiple organ compromise. Not all women 
with pre-eclampsia exhibit abnormal placentation and not all cases of abnormal 
placentation result in pre-eclampsia. Pre-eclamptic women who are obese, diabetic, 
with chromic hypertension multi-fetal gestation may have placentas of normal or 
large size without the characteristic features of abnormal placentation (Zhang et al., 
2006). Thus, pre-eclampsia can be divided into two types namely, 
a.) Placental pre-eclampsia → for those cases of pre-eclampsia with   
evidence of abnormal placentation. 
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b.) Maternal pre-eclampsia → to those cases where placenta is normal but  
there is an underlying chronic maternal condition associated to the  
     Pre-eclampsia (Redman and sergeant 2004) 
Here the normal adaptive inflammatory response that occurs with pregnancy is 
aggravated by maternal medical conditions to a point of decompensation that will 
manifest clinically as pre-eclampsia. 
Irrespective of etiology and mechanism of the disease, there are several 
pathophysiologic changes in pre-eclampsia, which includes haemodynamic 
changes due to alteration in blood volume and PVR, alterations of the hemostatic 
system and abnormal renal functions.   
I) Haemodynamic Changes:- 
 Maternal cardiac output is increased more than increased PVR in mild  
Pre-eclampsia. 
 On severe pre-eclampsia, there is a switch to normal or decreased cardiac 
output and elevated PVR (Hibbard et al 2004) using Doppler, Bosio et al 
(1998) formed that women with pre-eclampsia initially have increased CO & 
normal PVR, with worsening of the disease, there was a hemodynamic 
crossover to low CO and elevated PVR. 
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A) Changes in Blood Volume 
1. In mild pre-eclampsia → normal expansion of intravascular volume. 
2. In severe pre-eclampsia → due generalized vasoconstriction of 
capacitance vessels, the intravascular volume, which increases during  
normal pregnancy is minimal or completely absent 
3. The plasma volume increases and Haemoglobin and Haematocrit values 
decrease after delivery due to decreased vasospasm, excessive blood loss 
following delivery and mobilization of fluid from extracellular to 
intravascular compartment. 
B) Changes in PVR 
 Normotensive woman will show resistance to pressor effect of angiotensin II 
and catecholamine. 
 Patients destined to develop pre-eclampsia show progressive loss of 
resistance to pressor effect of angiotensin II & catecholamine. 
 In patients with chronic hypertension who may develop superimposed pre-
eclampsia, there is decrease in vascular resistance to the pressor effects of 
angiotensin II  
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II) Haemostatic abnormalities. 
These abnormalities develop in some women with pre-eclampsia. Among these 
commonly identified are: 
Thrombocytopenia (< 10%) 
 Some clotting factors are decreased and erythrocytes may show bizarre 
shapes and may undergo rapid hemolysis 
 The intensity and frequency of thrombocytopenia varies with the severity 
and duration of pre-eclampsia syndrome as well as the frequency with which 
platelet counts are performed (Heilmann& Colleagues 2007) 
 Overt thrombocytopenia <1,00,000 indicates severe disease. 
 After delivery, platelet count continues to decrease for the first day and 
usually increases progressively to reach a normal Level in 3-5 days. 
Other platelet abnormalities:-  
 Platelet activation with increased degranulation, thromboxane A2 release and 
decreased life span (Kenny & associates 2009) 
 The cause is unknown, immunological endothelial damage may be 
implicated  
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 Platelet bound and circulating platelet bindableimmunoglobulins are 
increased which suggest platelet surface alterations. (Samuels and 
Colleagues 1987)  
Hemolysis:- 
 Severe pre-eclampsia is frequently accompanied by evidence of hemolysis, 
semi-quantified  by elevated LDH levels 
 Also from schizocytosis, spherocytosis and reticulocytosis in peripheral 
blood (Cunningham and associates 1985, Pritchard & Colleagues 1954) 
 These derangements results from microangiopathic hemolysis caused by 
endothelial disruption with platelet adherence and fibrin deposition. 
 Sanchez- Ramoz and colleagues described increased erythrocyte membrane 
fluidity with HELLP syndrome. 
 These changes were due to serum lipid alterations (Cunningham & Co-
workers 1995) 
 Erythrocytic membrane changes, increased adhesiveness and aggregation 
may also facilitate a hyper-coagulation state (Gamzu and Co-worker 2001) 
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HELLP Syndrome:- 
In addition to hemolysis and thrombocytopenia, elevated serum liver transaminase 
levels were commonly found with severe pre-eclampsia and were indicative of 
hepatocellular necrosis (Chesley 1978 & Weinstein 1982) referred this condition as 
HELLP syndrome. 
Coagulation:- 
 Increased factor VIII consumption, increased levels of fibrinopeptides A & 
B and of fibrin degradation products and decreased levels of regulatory 
proteins – antithrombin III and protein C & S.  
 Coagulation aberrations are generally mild.  
 Routine laboratory assessment for coagulation is unnecessary in managing 
pregnancy associated hypertensive disorders (Barron & Colleagues 1999). 
 
Other Clotting Factors:- 
 Early onset pre-eclampsia is associated with thrombophilias, clotting factor 
deficiencies that lead to hyper coagulability. Association has been found 
between severe pre-eclampsia and thrombophilia particularly factor V 
Leiden and to a lesser extent MTHFRC67TT mutations (Morrison et al., 
2002). 
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 Fibronectin, a glycoprotein associated with vascular endothelial cell 
basement membrane, is elevated in women with pre-eclampsia (Brubaker & 
Colleagues 1992). 
III. Volume Homeostasis 
Endocrine changes:- 
 Plasma level of Renin, angiotensin II angiotensin 1-7, and aldosterone are 
decreased (Luft and colleagues 2009) 
 Secretion of Atrial Natriuretic peptide is increased in women with pre-
eclampsia (Borghi& associates 2000, Luf& Colleagues 2009). 
Fluid and Electrolyte changes:- 
 In severe pre-eclampsia, the volume of extracellular fluid, manifests as 
edema. The mechanism responsible for pathological fluid retention is 
thought to be endothelial injury. 
 In addition to Edema and proteinuria, these patients have reduced plasma 
oncotic pressure, which causes a filtration imbalance leading to 
displacement of intravascular fluid into the surrounding interstitium. 
 There is no change in electrolyte concentrations. 
 In eclampsia, there is a reduced pH and bicarbonate concentration due to 
lactic acidosis and compensatory respiratory less of carbon dioxide. 
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I. Kidney:- 
With development of pre-eclampsia, there may be a number of reversible 
anatomical and pathophysiological changes. 
 Glomerular filtration rate, filtration fraction and effective renal plasma flow 
all decrease in pre-eclampsia. 
 Glomerular endotheliosis, swollen intracapillary endothelial cells in the 
glomeruli, the hallmark of renal lesion of pre-eclampsia, represents the 
primary renal manifestation. The excess of SFLT-1 probably plays a major 
role in causation of glomerular endotheliosis. 
 The increased renal vascular resistance will cause a reduction in renal blood 
flow and this leads to decrease in glomerular filtration (Conrad and Co-
workers 2009) 
 Glomerular endotheliosis leads to block in the filtration barrier. Decreased 
filtration causes serum creatinine values to rise to 1 mg/ml or more 
(Linheimer and Colleagues 2008). 
 Urine sodium concentration is elevated.  
 Plasma uric acid levels are elevated in pre-eclampsia. The elevation exceeds 
the reduction in glomerular rate and is due to enhanced tubular reabsorption 
(Chesley& Williams 1945) 
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 Also from increased placental urate production compensatory to increased 
oxidative stress. 
 Diminished urinary excretion of calcium because of increased tubular 
reabsorption (Taufield and associates 1987) 
 Oliguria / anuria is a most important sign to look for in pre-eclampsia (Mac 
Gillivray 1983). It is a consequence of combination of glomerular 
endotheliosis, intrarenal vasoconstriction and hypovolemia. 
 Acute renal failure is a rare complication (1 in 10000-150000), It is a major 
cause of obstetric ARF. It is mostly caused by ATN, but sometimes due to 
bilateral cortical necrosis. 
 
II. Liver:-  
 Pathological changes in the liver are periportalhaemorrhages, ischemic 
Lessons and fibrin deposition. 
 Liver damage may vary from mild hepatocellular necrosis to severe liver 
injury with marked increase in liver enzymes, sub-capsular rupture and 
rarely even liver rupture. 
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Other organs:- 
 
Changes in other organs are involved only in severe cases. 
 
Brain → multiple petechial harmorrhages and larger haemorrhages in the cortex 
pons or mid brain. 
 
Heart → subendocardial petechial hemorrhages may be present in myocardium 
and in case of acute left ventricular failure, the left ventricular is dilated. 
 
Lungs → pulmonary edema. 
 
Adrenals → Haemorrhages and necrosis. 
 
Eye → purtscher retinopathy, retinal detachment 
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Prediction of Pre-eclampsia 
Measurement of a various biological, biochemical and biophysical markers 
associated in the pathophysiology have been proposed to predict preeclampsia. 
Studies have been done to identify early markers of defective placentation, 
decreased placental perfusion, endothelial cell activation and dysfunction, and 
activation of coagulation. 
Unfortunately, most of these tests have poor sensitivity with poor positive 
predictive values for pre-eclampsia (Conde-Agudelo and Colleagues 2009, 
Lindheimer and associates 2008 Sibai 2003). There is a constant search for a 
screening test, which is reliable, accurate and cost effective. 
I. Placental perfusion / vascular resistance – Related test 
i. Provocative Pressor Tests:-  
There are 3 tests extensively evaluated to assess blood pressure increase in 
response to a stimulus. Sensitivity of all 3 tests range from 55-70% with spasticity 
of approx 85% (Conde – Agudelo& associates 2009) 
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a.) The Roll-over test:- 
 Measures the hypertence response in women at 28-32 weeks,who are resting 
in the left lateral decubitus position and then “roll over” to assume a supine 
position. 
 Test is considered positive if there elevation of 20mm Hg or more in 
diastolic blood pressure when patient rolls over from left lateral position to 
supine position (Gant et al) 
 It has poor sensitivity, poor specificity and is of limited clinical value. 
b.) The isometric exercise test :- 
 Employs the same principle by squeezing a handball or hand grip test. 
 A increase of 15mm Hg in systolic BP during hand grip test predicted the 
development of gestational hypertension  
 It has sensitivity of 81.8% and specificity of 68.4%, but has poor 
reproducibility. 
c.) Angiotensin II infusion test:- 
 It is preformed by giving incrementally increasing doses intravenously, and 
the hypertensive response is quantified. 
 It is based on the loss of refractoriness to angiotensin II in pregnant women 
who later develop pre-eclampsia. 
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 It has high false negative and false positive results. Test is expensive, time 
consuming and at times unreliable. 
 
ii. Uterine artery Doppler velocimetry:- 
 Faulty trophoblastic invasion of the spiral arteries, results in diminished 
placental perfusion and upstream increased uterine artery resistance. 
 Increase uterine artery velocitmetry determined by Doppler ultrasound in the 
first or middle trimester should provide indirect evidence of this process & 
serves as predictive test (Gebb and associates 2009) 
 Increased flow resistance results in an abnormal waveform represented by 
increased Diastolic notch at 16-20 weeks gestation have been found to be 
useful prediction of pre-eclampsia. 
 iii.Midtrimester mean arterial pressure:- 
 Mean arterial pressure (Systolic + (2/3) × Diastolic) > 90mm Hg  in mid  
trimester was proposed to predict  pre-eclampsia. 
 Low sensitivity and low specificity. 
 Recent review suggests that MAP in mid trimester is a better predictor of 
gestational hypertension than pre-eclampsia (Conde-Agudelo et al 1993). 
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iv. 24 hours ambulatory BP monitoring:- 
24 hours mean diastolic pressures greater than 71 mm Hg was been used to predict  
the development of pre-eclampsia or gestational hypertension with a sensitivity of 
22% and positive predictive value of 15%. 
 
II. Fetal – Placental unit Endocrine Dysfunction. 
A number of serum analysis have been proposed to predict pre-eclampsia however, 
none of these tests have been shown to be clinically beneficial for hypertension 
prediction. 
 
III. Endothelial Dysfunction / Oxidative stress. 
Fibronectin:- 
 These are high molecular weight glycoprotein released from endothelial 
cells and extracellular matrix following endothelial injury. 
 The plasma concentrations of these are elevated in women with pre-
eclampsia (Stubbs & Colleagues 1984) 
 Recent review concluded that neither cellular nor total fibronectin was 
clinically useful to predict pre-eclampsia (Leeflang and associates 2007). 
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IV. Oxidative stress:- 
a) Increased levels of lipid peroxides coupled with decreased antioxidant 
activity have raised the possibility that markers of oxidative stress might 
predict pre-eclampsia (Walsh 1994) 
Eg:-Malondialdehyde - marker of lipid peroxidation. 
Other markers are a variety of pro- oxidation or potentiators of pro-oxidants 
including iron, transferin and ferritin blood lipid and anti oxidants. These are not 
predictive but treatments to prevent pre-eclampsia with some of these have been 
studied. 
b) Hyperhomocysteinemia causes oxidative stress and endothelial cell 
dysfunction and is found in pre-eclampsia. 
Although women with elevated serum homocysteine levels at mid pregnancy had a 
3-4 fold risk of pre-eclampsia, these tests have not shown to be clinically useful  
predictors (D’Anna 2004) Mignini 2005, Zeeman 2003 and their colleagues. 
V. Angiogenic Factors:- 
 Imbalance between pro angiogenic and antiangiogenic factors is 
associated with the pathogenesis of pre-eclampsia. 
 Serum levels of pro angiogenic factors such as vascular endothelial 
growth factor (VEGF & placental growth factor (PlGF) begin to decrease 
before clinical pre-eclampsia develops. 
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 At the same time, levels of some antiangiogenic factors such as soluble 
forms like tyrosine Kinase-1 (SFLT-1) and soluble endoglins (SEng) are 
increased (Maynard and Colleagues 2008). 
 The measurements of these may predict pre-eclampsia. The sensitivity 
ranged from 59-100% & specificity ranged from 43-100%. (Conde-
Agudelo and associates 2009). 
 The predictive accuracy was higher for early-onset pre-eclampsia. 
 Until better substantiated, their clinical usefulness is not recommended  
(Widmer& Colleagues) 
VI. Free Fetal DNA:- 
 Free fetal DNA can be detected in maternal plasma by polymerase chain 
reaction (Lo and colleagues 1997). 
 Fetal – maternal cell trafficking is increased in pregnancies complicated by 
pre-eclampsia. 
 Fetal DNA is released from apoptosis of cytotrophoblast (Difederico& 
colleagues 1999) 
 From these review Conde-Agudelo& associates (2009) → Concluded that 
free fetal DNA quantification is not useful for prediction purposes. 
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VII. Renal Dysfunction – Related tests  
i. Serum uric acid  
 Hyperuricemia may be one among the earliest laboratory manifestations of 
pre-eclampsia  (Powers and associates 2006) 
 Excretion of uric acid  is reduced due to decreased glomerular filtration, 
increased tubular reabsorption and decreased secretion (Lindheimer& 
colleagues 2008). 
 Sensitivity ranged from 0-55% & specificity from 77 to 95% (Cnossen& 
associates) 
ii. Microalbuminuria:- 
 Sensitivity 7-90% & specificity 29-97% (Conde-Agudelo& associates) 
indicates poor clinical predictive value. 
 Radioimmunoassay can detect the value of > 11µgm/ml which indicate 
positive test. 
iii. Fasting urine albumin - Creatinine ratio:- 
 Ratio of ≥ 16 indicates positive screening (Nakamura et al). False positive 
57%, False –ve 6%. 
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iv. Urine kallikrein - Creatinine ratio:- 
 Ratio of ≤ 170 may predict future development of pre-eclampsia (Camphell 
et al 1987, Miller 1996 
v. Urinary calcium excretion:- 
 Sanchez – Romos 1991 → 24kg urinary calcium excretion less than 12 mg / 
dl had positive predictive value of 91% sensitivity of 88%. 
vi. Urinary calcium - creatinine ratio:- 
 Low calcium - creatinine value of < 0.04 is used in prediction of pre-
eclampsia (Rodriquez et al).  
    Similar studies related to urine calcium – creatinines are as follows:  
 In 1984, Pederson E.B & Co-workers concluded that the increased renal 
excretion of calcium during normal pregnancy and decreased calcium 
excretion in pre-eclampsia might be due to changes in kidney function. 
 1987, Taufield& Co-workers concluded that measurement of urine calcium 
might be useful to distinguish pre-eclampsia from other forms of Gestational 
hypertension. 
 In 1988, Rodriguez H.M & Co-workers studied first morning Urine sample 
in pregnant women between 24 and 34 week gestation for the presence of 
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micro albuminuria and calcium / creatinine ratio was estimated. Ca /Cr ratio 
< 0.04 and micro albumin < 11µg / dl as predictor for pre-eclampsia. 
 Urinary calcium < 12 mg /dl may help to distinguish pre-eclampsia from 
other hypertensive disorders of pregnancy. 
 1991, Misiani.R and Co-workers → Microalbuminuriapreceeded the onset 
of hypertension. 
 1991 Annai T and Co-workers → Concluded that determination of the 24hr 
urinary calcium excretion / Ca /Cr ratio in random urine sample is reliable 
index of preeclampsia. 
 1992 → Suzuki Y & Co-workers –urinary calcium excretion may be useful 
marker for preeclampsia. 
 1995 – Ozcan T and co workers: Suggested that single urine calcium to 
creation ratio might be an effective marker for predicting pre-eclampsia in 
high risk population. 
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Prevention 
Variety of strategies is used to prevent or modify the severity of pre-eclampsia In 
general none of these have been found to be clinically efficacious 
Dietary Manipulation:- 
1) Low Salt diet:- 
 One of the earliest effort to prevent pre-eclampsia was salt restriction 
(De snoo 1937). 
 First Randomised trial was done by knuist& colleagues 1998, showed that 
sodium restricted diet were ineffective in preventing pre-eclampsia. 
2) Calcium Supplementation:- 
 Women with low dietary calcium intake were at increased risk for 
gestational hypertension (Belizan and villar 1980) 
 Unless women are calcium deficient, supplementation has no salutary effects 
(Sibai and Cunningham 2009) 
3) Fish oil supplementation:- 
 The  fatty acids found in some fatty acids have cardio protective effect – 
EPA Eicosapentaenoia acid & ALA – alpha linoleic acid  
 Would prevent inflame amatory – mediated atherogenesis. 
53 
 
 Randomised control trich conducted so far have shown no such benefits. 
(MAKRIDES 2006) 
4)Antioxidants:- 
 Naturally, occurring antioxidants are vit C & E. 
 Women who developed pre-eclampsia were found to have reduced plasma 
levels of these two vitamins (Raijimakes and associates 2004). 
 Several Randomized studies have been done; none of them showed 
reduction of pre-eclampsia in women given antioxidant vitamins compared 
with those given placebo.  
Medical measures:- 
Antihypertensive drugs:- 
  Patients with chronic hypertension are at increased risk for pre-eclampsia. 
 Several randomized trials have been carried out to evaluate various anti 
hypertensive drugs in reducing the incidence of superimposed pre-eclampsia 
 A critical analysis of these failed to demonstrates such a reduction (Sibai and 
Cunningham 2009) 
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Antithrombotic agents:- 
 Antithrombotc agents might reduce the incidence of pre-eclampsia.  
Low dose aspirin 
 Oral dose of 50-150 mg per day, aspirin can inhibit effectively the 
biosynthesis of platelet thromboxane A2 with minimum effect on vascular 
prostacyclin production (Wallenburg and associates 1986). 
 Due to marginal benefits, it is reasonable to individualisethe  use of low dose 
aspirin to prevent recurrent pre-eclampsia (Sibai and Cunningham 2009). 
 Collaborative low dose Aspirin study in pregnancy (CLASP), a large 
randomized controlled trial reported a reduction of 12% in pre-eclampsia, 
which was non-significant. 
 Some benefit was noted in a small subset of women, who were likely to 
develop early onset pre-eclampsia.  
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Calcium 
It is the most abundant mineral in body.   Adult body contains approximately total 
calcium of 1 kg. 99% is in the form of calcium phosphate salts, in the skeleton 
The rest is present in extra cellular fluid, which contains 22.5m mol of which 9m 
mol is in the serum. Over a period of 24 hrs, 500m mol of calcium is exchanged 
between the bone and extra cellular fluid. 
Biological functions:- 
1) Structural function → supporting material in bone (Calcium phosphate) 
2) Signaling functions → Inter cellular calcium function as second messenger for 
harmones. 
3) Enzymatic function → Coenzyme for clotting factors. 
 Calcium also helps in transmission of nerve impulse by releasing acetyl   
choline from pre-synaptic terminal 
 Causes contraction of muscles 
Normal Range:- 
Normal total calcium      = 2.2 – 2.6 m mol/L or 9-10.5 mg/dl 
Normal ionized calcium = 1.1 to 1.4 m mol/L or (4.5 - 5.6 mg/dl) 
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The biological activity of calcium is mainly by ionized calcium. Total calcium is 
bound to Albumin hence its serum concentration varies with concentration of 
serum Albumin. 
Absorption:- 
In a normal diet, about 25m mol of calcium enters the body, of this 10m mol is 
absorbed in small intestine and 5m mol is excreted in the feces. Thus about 5m mol 
of calcium is available per day. 
Calcium may be absorbed by two methods 
a) Active process → which is vitamin D dependent 
b) Passive process → occurs in jejunum and ileum when calcium intake is high. 
Active process:- 
Calcium is absorbed by passing through the ion channels. Calbindin is the vit D 
dependent binding protein present in the epithelial cells of intestine, which along 
with ion channels and calcium pumps actively transports calcium into the body  
This process occurs actively in Duodenum portion when calcium intake is less. 
 
 
 
57 
 
EXCRETION 
The Kidneys excrete about 250m mol / day, reabsorbs 245 m mol. Thus, a net loss 
in urine is about 5m mol / day. The presence of phosphorous decreases calcium 
excretion. 
Regulation:- 
Calcium homeostasis mechanism is multifactorial. 
Involves calcium itself and other related minerals such as magnesium & 
phosphorous. And three calcitropic hormones like parathyroid hormone, calcitonin, 
and active form of vitamin D3 (1,25 – dihydroxycholecalciferol). 
 Calcium homeostasis involves 3 principal organs. 
 → Gastro intestinal Tract 
 → Bone 
 → Kidneys 
a) Gastro intestinal Tract:- 
At high levels of calcium intake, synthesis of calcitrol is decreased, which 
decreases calbindin synthesis and thus decreases rate of active calcium absorption. 
The opposite phenomenon occurs with decreased dietary calcium intake. 
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b) Kidneys:- 
Of 250m mol / day plasma calcium filtered through glomeruli, 98% is reabsorbed 
from proximal tubules.  
It is a passive process, not regulated by hormone. 
In the distal parts of the nephrons (Distal convoluted tubules, connecting tubules 
and initial portion of collecting duct) 15% of the filtered load of calcium is 
reabsorbed. 
This reabsorption is an active process occurring against electrochemical gradient. 
It is subjected to hormonal regulation mainly by parathormone and also by 
calcium, calcitonin, estrogens and androgen.  
 
c) Bone:- 
The calcium influx into bone equals rate of efflux hence bone mass remains 
constant. Turnover in a day is about 5m mol. 
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Hormonal Regulation 
 
 
a.) Parathyroid harmone:- In extra cellular fluid, low levels, ionized calcium 
concentration stimulates PTH secretion, high levels inhibit it. Action of PTH 
is to increase extracellular calcium levels and decrease phosphate levels 
mainly by Bone resorption, Intestinal absorption and Kidney reabsorption. 
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b.)  Vitamin D → vit D3 after ingestion or synthesized from UV light is 
hydroxylated to 25 hydroxy vitamin D3 (The principal circulating form of 
vitamin). 
This form is normally hydroxylated at 1α position in Kidney, placenta and decidua 
to form 1, 25-dihydroxycholecalciferol facilitated by PTH, low calcium levels and 
phosphate levels & its actions opposed by calcitonin. 1, 25-
dihydroxycholecalciferol is the biologically active form.  It stimulates resorption 
of calcium from bone and absorption of calcium from small intestines.  
Calcium in normal pregnancy and pre-eclampsia. 
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The Developing fetus imposes a significant demand on maternal calcium 
homeostasis. Eg; Fetal skeleton accretes 30g of calcium by term, 80% of which is 
deposited during the last trimester. The demand of which is met by doubling of 
intestinal calcium absorption mediated by 1, 25, dihydroxy vitamin D3 (Kovacs 
and Fuleihan 2006). 
Total calcium levels decline during normal pregnancy due to lowered plasma 
albumin concentration levels of serum ionized calcium remains unchanged (Power 
& associates 1999). 
Plasma concentrations of parathyroid hormone decrease during first tri mester and 
then increases progressively throughout the remainder of pregnancy (Pitkin and 
associates 1979). This increase is due to lowered calcium concentrations as a result 
of increase in plasma volume, glomerular filtration rate and maternal transfer of 
calcium to fetus. Estrogen blocks action of PTH on bone resorption thus increases 
its levels. Thus it results in physiological hyperparathyroidism of pregnancy, which 
supplies the fetus with adequate calcium.1, 25 dihydroxy vitamin D3 levels are 
increased during normal pregnancy (Weisman and co-workers 1979) probably 
(placental &decidual origin) 
In Pre-eclampsia, due to defective placenta, there is decrease in levels of 1, 25 
dihydroxyvit D3 which causes decrease in GI absorption of calcium. Thus there is 
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low ionized calcium. During pregnancy due to transfer of calcium to fetus from 
mother, there is increased calcium uptake by placenta resulting in hypocalcemia, 
this in turn increases PTH. Hence, there is reduced placental perfusion and renal 
damage which leads to decreased synthesis of 1, 25 dihydroxyvit D3 which would 
stimulate PTH to increase reabsorption of Ca
++ 
from distal tubules and proximal 
tubules resulting in hypocalciuria. 
 Important changes:- 
 Serum ionized concentration of calcium is lower in pre-eclampsia. 
 Lower calcium excretion. 
 Lower 1, 25 dihydroxyvit D3 
 Increased PTH levels. 
Lower calcium intake will increase BP due to vasoconstriction by stimulating 
release of renin from Kidneys and / or PTH.  
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Creatinine 
 It is derived from Greek word Kreas meaning flesh. It is a break down 
product of muscle creatinine phosphate  
 Produced at a constant Rate by the body  
 Creatinine constitutes 0.5% of total muscle mass. 
 It is filtered by the Kidneys (Glomerular filtration and proximal Tubular 
secretion) 
 There is little or no tubular reabsorption of creatinine. When the filtering by 
the Kidneys is decreased, creatinine in blood increases. 
 Hence creatinine values in blood & urine can be used to estimate the 
creatinine clearance (Cr Cl) which reflects the glomerular filtration rate. 
 Normal urine creatinine levels are 1-2 gm / day. 
 Normal plasma creatinine 0.8-1 mg / dl. 
 In normal pregnancy, there is decrease in plasma creatinine and increase in 
24 hrscreatinine clearance  
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 In pre-eclampsia, due to diminished renal perfusion and glomerular filtration 
there is elevation in plasma creatinine. 
Micro Albuminuria 
 It is a marker for endothelial dysfunction. 
 Micro albuminuria occurs when there is small amount of albumin leaks from 
Kidney into urine suggesting abnormally high permeability for albumin in 
the renal glomerulus  
 Micro albuminuria is defined as urinary excretion of albumin that is 
persistently above normal but cannot be detected by urine dipstick methods. 
 Diagnosed from 24hrs urine collection value of 20-200mg / min or elevated 
concentrations of 30-300 mg / L on at least two occasions. 
 It reflects the presence of generalized vascular damage 
 During normal pregnancy, the urine albumin excretion remains within 
normal range. There may be small increase in albumin excretion during the 
third trimester due to increased glomerular permeability and due to 
decreased tubular protein absorption  
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 In pre-eclampsia there is decrease in GFR and renal blood flow,leading to 
decreased filtration fraction. 
 Glomerular endotheliosis characterized by enlarged and swollen glomeruli, 
which is mainly due to hypertrophy of the intracapillary cells, which 
encroach on the capillary lumen resulting in bloodless glomerulus.  
 These changes are responsible for the microalbuminuria in initial stages & 
later proteinuria in pre-eclampsia. 
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AIM OF THE STUDY 
To determine predictive values of decreasing urinary calcium to creatinine ratio 
and microalbuminuria for preeclampsia, in a spot urine sample, in asymptomatic 
pregnant women between 20 to 24 weeks of gestation in order to recommend it as 
screening test for preeclampsia 
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MATERIALS AND METHODS 
This test was conducted at RSRM Lying in hospital, Royapuram, Chennai. 
Attached to Stanley Medical College. 
STUDY PERIOD 
The study period was from October-2012 to November-2013 
STUDY DESIGN - Prospective study. 
200 asymptomatic pregnant women attending routine antenatal care who could be 
followed until term at RSRM Lying in hospital were selected.  
 
INCLUSION CRITERIA 
  20–24 weeks of gestation age  
 Asymptomatic women who attended the antenatal OPD at RSRM Lying in 
hospital, Royapuram- Chennai. 
 
EXCLUSION CRITERIA 
 Chronic hypertension 
 Renal disease 
 Diabetes 
 Albuminuria in dip-stic method 
 BP >140/90 
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METHODOLOGY 
 Pregnant women included in the study were counseled, given proforma and 
a written informed consent was obtained. 
 Patients detailed history was taken. 
 clinical and routine obstetric examination was done 
  Blood pressure was recorded in sitting position in right arm. Korotkoff   V 
was used to measure diastolic blood pressure. 
  Routine antenatal tests were done. 
 Single spot urine sample irrespective of day-time was collected in clean 
sterile universal bottle without any preservative. 
 Urine samples were sent to biochemistry laboratory, RSRM Lying  in 
hospital without delay 
 urine tested for microalbumin, calcium and creatinine using commercially 
available kits(ROBONIK LABORATORIES) 
 O Cresolphthalein complex reaction was used to estimate calcium. 
 Jaffes method was used to estimate creatinine. 
 Microalbumin was detected by immunometric assay.  
  Values of urinary calcium - creatinine ratio calculated and value of 
microalbumin noted. 
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 After initial workup, patients were followed thereafter in the antenatal clinic 
till the time of delivery.  
 During follow up, they were evaluated by detailed history of symptoms of 
preeclampsia and imminent eclampsia such as edema, nausea, vomiting, 
epigastric pain, decreased urine output and visual disturbances.  Clinical 
and routine obstetric examination was done. Blood pressure was measured 
and urine was tested for protein by dipstick method.  
   Pre-eclampsia was defined as systolic arterial blood pressure ≥140mmHg 
and/or diastolic arterial blood pressure ≥ 90mm Hg with ≥300 mg/24h 
proteinuria (dipstic method) 
 The number of patients who developed preeclampsia  was noted and 
correlation studied 
 Based on these criteria the women studied were categorized as those who 
developed pre-eclampsia and those who remained normotensive. 
 Calcium - Creatinine ratio less than or equal to 0.04 were considered test 
positive and those with a ratio of >0.04 were considered test negative. 
 Urine microalbumin levels between 30 to 300mg/L were considered test 
positive for microalbuminuria and those with levels <30mg/L were 
considered test negative. 
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 Predictive values of calcium to creatinine at less than or equal to 0.04 and 
microalbuminuria determined by statistical analysis. 
 
STATISTICAL METHODS: 
Chi square test and Fisher Exact test has been used to find the significant 
association of findings of preeclampsia and CCR and microalbuminuria. 
p value : 
a)  ≤ 0.01  strongly significant 
b)  0.01- 0.05  moderately significant 
c)  0.05 - 0.1  significant 
Area under Receiver Operator Curve (ROC) was used to find the predictive values 
of CCR at less than or equal to 0.04 and microalbuminuria for preeclampsia. 
a) 0.9 – 1 :  Excellent test 
b) 0.8 – 0.9  : Good test 
c) 0.7 – 0.8  : Fair test 
d) 0.6 – 0.7  : Poor test 
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ESTIMATION OF URINARY CALCIUM BY   
ORTHO - CRESOLPHTHALEIN  COMPLEXONE REACTION 
 
Principle : 
 In alkaline medium, ortho-cresolpthaleincomplexone reacts with calcium 
forming red violet colour.                 
 Interference by magnesium is eliminated by addition of 8 hydroxyquinoline 
in the reagent 
 The colour intensity is directly proportional to concentration of calcium in 
the sample. 
 Measurement of calcium is done in coloured complex at wavelength of 
570nm -580 nm. 
 
ESTIMATION OF URINARY  CREATININE BY  JAFFE „S METHOD 
Principle: 
Creatinine forms a coloured orange red complex in an alkaline picrate solution. 
The colour intensity obtained is directly proportional to the amount of creatinine in 
the sample. 
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ESTIMATION OF URINE MICROALBUMIN BY  
IMMUNOMETRIC ASSAY  
Principle: 
Microalbumin in urine is measured by turbidimetric immunoassay, which 
measures the reduction in light transmission caused by particle formation and 
quantifies the residual light transmitted. 
It is based on agglutination reaction. Albumin present in the sample forms an 
insoluble complex producing a turbidity, which can be measured at wavelength of 
340 nm. Turbidity corresponds to the concentration of albumin present in the 
sample.   
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RESULTS 
DISTRIBUTION OF PREGNANT WOMEN 20 – 24 WEEKS GESTATION 
IN STUDY GROUP ACCORDING TO AGE 
 
                                            Table-1 
Age in years Number percentage 
< 20 52 26 
21 -30 131 65.5 
>30 17 8.5 
total 200 100 
 
In our study, majority 131 (65.5%) out of 200 women were in the age group of 21 
to 30 years, 52 (26%) were in the age group of below 20 years, 17(8.5%) were in 
the age group of above 30 years of age.  
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DISTRIBUTION OF PREGNANT WOMEN 20 – 24 WEEKS GESTATION 
IN STUDY GROUP ACCORDING TO AGE 
 
 
Figure-1 
Distribution of Age group
< 20
21 -30
>30
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DISTRIBUTION OF PREECLAMPSIA IN STUDY GROUP ACCORDING 
TO AGE GROUP 
                                                     Table-2 
 
Among who developed preeclampsia, 12(46.2%) were in the age group of 21-30 
years,9(34.6 %) were below the age group  of 20 years and 5( 19.2%) above 30 
years of age. 
 
 
 
 
 
 
Age in years Developed preeclampsia  normotensives Total 
<20 9(4.5%) 43(21.5%) 52(26%) 
21-30 12(6%) 119(59.5%) 131(65.5%) 
>30 5(2.5%) 12(6%) 17(8.5%) 
Total 26(13%) 174(87%) 200(100%) 
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DISTRIBUTION OF PRE-ECLAMPSIA IN STUDY GROUP ACCORDING 
TO AGE GROUP 
 
Figure-2 
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DISTRIBUTION OF STUDY GROUP  ACCORDING TO PARITY 
 
                                                 Table-3 
Obstetric code number Percentage 
Primi 124 62 
multi 76 38 
total 200 100 
 
 
In this study, out of 200 women 124(62%) were primigravida and 76(38%) 
were multigravida.  
 
 
 
 
 
 
 
 
 
81 
 
DISTRIBUTION OF STUDY GROUP  ACCORDING TO PARITY 
 
 
Figure-3 
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DISTRIBUTION OF PRE-ECLAMPSIA ACCORDING TO PARITY 
 
Table-4 
 
 Among those who developed preeclampsia, 17(65.4%) were 
primigravida and  9 of them ( 34.6%) were multigravida. 
 
 This shows that the incidence of preeclampsia  in primigravida is  
higher than the multigravida. 
 
 
 
Obstetric code Developed 
preeclampsia 
normotensive Total 
Primi 17(8.5%) 107(53.5%) 124(62%) 
Multi 9(4.5%) 67(33.5%) 76(38%) 
total 26(13%) 174(87%) 200(100%) 
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DISTRIBUTION OF PRE-ECLAMPSIA  ACCORDING TO PARITY 
 
Figure-4 
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URINE CALCIUM –CREATININE RATIO(UCCR) AND DEVELOPMENT 
OF PRE-ECLAMPSIA  
 
Table 5 
 
 Among the 200 women studied,23(11.5%) were test positive-UCCR of less 
than or equal to 0.04 and 177(88.5%) were test negative-UCCR >0.04. 
 
 Among the women who were test positive for UCCR, 19(82.6%) developed 
preeclampsia and those with test negative for UCCR,7(4%) developed 
preeclampsia. 
 
 
UCCR Developed 
preeclampsia 
normotensives total 
Test positive 19(9.5%)         4(2%)      23(11.5%) 
Test negative         7(3.5)      170(85%)     177(88.5%) 
total         26(13%)       174(87%)     200(100%) 
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URINE CALCIUM –CREATININE RATIO (UCCR) AND DEVELOPMENT 
OF PRE-ECLAMPSIA  
 
 
Figure-5 
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URINE MICROALBUMIN AND DEVELOPMENT OF PRE-ECLAMPSIA 
 
Table-6 
Urine 
microalbumin 
Developed 
preeclampsia 
normotensive Total 
Positive 16(8%) 26(13%) 42(21%) 
Negative 10(5%) 148(74%) 158(79%) 
total 26(13%) 174(87%) 200(100%) 
 
 
 Among the 200 women studied,42(21%) were test positive for urine 
microalbumin-30 to 300mg/L  and 158(79%) were test negative<30mg/L. 
 
 Among the women with test positive for urine microalbumin,16(38.1%) 
developed preeclampsia and of those with test negative 10(6.3%)developed 
preeclampsia. 
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URINE MICROALBUMIN AND DEVELOPMENT OF PRE-ECLAMPSIA 
 
 
Figure-6 
 
 
Urine Micro Albumine
Pos itiveNegative
C
o
u
n
t
160
140
120
100
80
60
40
20
0
Outcome
Normal
Developed Preeclamps
ia
88 
 
DISTRIBUTION OF PRE-ECLAMPSIA ACCORDING TO  
WEEKS OF GESTATION 
 
Table-7 
Gestation age (weeks) number 
<35 2 
36-37 10 
38- 40 14 
total 26 
 
 
 In this study, 14 patients developed preeclampsia at 38 to 40 weeks, 10 
patients developed at 36 to 37 weeks  and 2 of them developed at gestation 
age of less than 35 weeks. 
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DISTRIBUTION OF PRE-ECLAMPSIA ACCORDING TO 
WEEKS OF GESTATION 
 
Figure-7 
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ASSOCIATION  OF URINE CALCIUM – CREATININE RATIO AND  
PRE-ECLAMPSIA 
                                                Table-8 
UCCR < 0.04 Developed  
PRE-ECLAMPSIA 
NORMOTENSIVE 
Positive (23)         19(9.5%)           4(2%) 
Negative (177)         7(3.5%)        170(85%) 
total       26(13%)        174(87%) 
 
Using  Chi square test/Fisher Exact test: 
p value   -     <0.001 
Statistical  accuracy-94.5% 
Sensitivity-73.1% 
Specificity-97.7% 
Positive predictive value-82.6% 
Negative  predictive value-96% 
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ASSOCIATION OF URINE CALCIUM – CREATININE RATIO  
AND PRE-ECLAMPSIA 
 
 
Figure-8 
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ASSOCIATION  OF MICROALBUMINURIA AND PRE-ECLAMPSIA  
 
Table-9 
Urine microalbumin Developed 
preeclampsia 
normotensive 
Positive(42)        16(8%)      26(13%)  
Negative(148)        10(5%)      138(74%) 
 
Using Chi square test/Fisher Exact test: 
p value   -   <0.001  
Statistical  accuracy – 82% 
Sensitivity-61.5% 
Specificity- 85% 
Positive predictive value-38.1% 
Negative  predictive value-93.7% 
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ASSOCIATION  OF MICROALBUMINURIA AND PREECLAMPSIA  
 
 
Figure-9 
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PREDICTIVE VALUES OF URINE CALCIUM –CREATININE RATIO 
AND MICROALBUMINURIA FOR PRE-ECLAMPSIA, USING AREA 
UNDER RECEIVER OPERATOR CURVE (ROC) 
 
Table-10 
 AUC SE 95% CI  REMARKS 
UCCR 0.901 0.39 0.825-0.997 Good test 
Microalbuminuria 0.709 0.059 0.593-0.824 Fair test 
 
AUC – Area Under the Curve 
SE – Standard Error 
CI – Confidence Interval 
 
 When predictive value of urine calcium – creatinine ratio was calculated 
using area under curve of ROC it was found that UCCR at less than or equal 
to 0.04 was a good test. 
 Predictive value of microalbuminuria for preeclampsia using area under 
curve of ROC showed that it was  only a fair test for prediction of 
preeclampsia. 
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DISCUSSION 
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DISCUSSION 
Our present study was a prospective study comprising 200 asymptomatic pregnant 
women between 20 -24 weeks of gestation. Urine calcium- creatinine ratio and 
microalbumin was estimated from a single spot urine test .Similar studies were 
done by Sheela CN, Beena S R between 20 to 24 weeks. Kazeroni T et al  at 20 to 
24 weeks, Rodriguez H M  between 24 and 34 weeks, DayaSirohiwal et  al 
between 20- 28 weeks.  
 
Incidence of pre-eclampsia increases with extremes of age. 46.2% of women with 
pre-eclampsia were in the age group of 21-30years followed by 34.6% women 
were <20years and 19.2% were above 31years in our study. 
Pre-eclampsia is more common in primigravida. 
 
In our study, 65.4% of women with Preeclampsia were primigravida and 36.4% of 
women with preeclampsia were multigravida. Karith J et al  showed that nulliparity 
with decreased calcium -creatinine ratio were  at high risk for developing pre-
eclampsiaHusselman (1924) showed that primigravida were at eight times higher 
risk to develop eclampsia than multigravida.  
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In this study, urinary calcium/ creatinine ratio was lower in women with 
preeclampsia when compared to Normotensive women. Statistical analysis showed 
significant correlation of urinary calcium – creatinine ratio between women who 
developed Preeclampsia and Normotensive women with p value of < 0.001. These 
findings were similar to the studies of Hellen Rodriguez M et al , Ozcan T et.al , 
Patricia A devine et.al , Das Gupta mandira et al, Kazerooni T et.al , Kar J et.al , 
Suzuki Y et.al. 
 
In our study, 23(11.5%)  out of 200 were CCR positive (<0.04) and 177(88.5%) 
were CCR negative (>0.04). Among women who developed pre-eclampsia, 
19(82.6%) were tested positive and 7 (4%) were tested negative. Among 
Normotensive women 4 (17.4%) were test positive and 170 (96%) were test 
negative. 
 
In our study ,urine calcium-creatinine ratio(CCR) at less than or equal to 0.04 in a 
spot urine sample had sensitivity of 73.1%, specificity of 97.7%, positive 
predictive value of 82.6%, negative predictive value of 96%, and diagnostic 
accuracy of 94.5% .Urine calcium – creatinine ratio was found to be a good test for 
predicting preeclampsia  
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These results were similar to studies done by Rodriguez H M and co-workers in 
1988 also estimated the CCR at 0.04, they analyzed a sensitivity less of 70%, 
specificity of 95%, PPV of 64%, NPV of 96% for prediction of pre-eclampsia. 
Study conducted by  Sheela CN, Beena SR, MhaskarArun et al  in 2011, reported 
that calcium –creatinine ratio at less than or equal 0.04 in spot urine sample 
showed a sensitivity of 69%, specificity of 98 %, PPV of 85.6% and NPV of 
95.5%.They found it to be a good test. Sudan et .al, reported sensitivity of 68% and 
sensitivity of 70%. Ozcan et al reported that CCR might be an effective marker of 
preeclampsia. In addition, studies done by Kazeroomiet .al. and Kar et evaluated 
predictive values of CCR at 0.04 was a satisfactory test for prediction of 
preeclampsis. 
 
Thus, the above mentioned authors, in their studies gave results which showed that 
decreased urinary CCR in single spot sample has a significant association with 
development of pre-eclampsia and it can be used as screening test. 
 
In our study, 42(21%)  out of 200 were urine microalbumin test positive (30 – 
300mg/L) and 158(79%) were test negative (<30mg/L). Among women who 
developed pre-eclampsia, 16(61.5%) were tested positive and 10(38.5%) were 
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tested negative. Among Normotensive women 26(14.9%) were tested positive and 
148(85%) were test negative. 
 
Statistical analysis for urine microalbumin showed significant p-value of < 0.001. 
The cut of value for urine microalbumin>30-300mg/L was found to have 
sensitivity 61.5%, specificity 85.1%, positive predictive value 38.1%, negative 
predictive value 93.7%, and diagnostic accuracy of 82% for prediction of pre-
eclampsia. It was found to be a fair test. 
Salako et al reported that a single estimation of microalbuminuria had a high 
sensitivity (88.9%) but a low PPV (22%). Shaarawy et.al.evaluated the clinical 
value of microtransfferrinuria and microalbuminuria in prediction of preeclampsia 
in asymptomatic women and  concluded that microtransfferrinuria was a more 
sensitive marker than microalbuminuria. Chhabraet.al  found that estimation of 
microalbuminuria around 18 weeks of gestation was useful in primigravida 
 
Hence  urine calcium-creatinine ratio was found to be a good test for prediction of 
pre-eclampsia and can be used as screening test Microalbuminuria was found to be 
a fair test and further studies are needed recommend it as a screening test. 
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SUMMARY 
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SUMMARY 
 
 In our study , majority (65.5%) were in  the age group of 21 to 30 years,26% 
were in the age group of below 20 years,8.5% were in the age group of 
above 30 years of age 
 
 Preeclampsia developed in 46.2% of study group who were in the age group 
of 21-30 years,34.6% who were below the age group of 20 years and  19.2% 
who were  above 30 years of age. 
 
 65.4% of primigravida developed preeclampsia and 34.6% of  multigravida 
developed preeclampsia 
 
 Among the women who were test positive for urine calcium – creatinine 
ratio, 19 (82.6%) developed preeclampsia. This was statistically highly 
significant. 
 
 Among those with test positive for urine microalbumin, 16(38.1%) 
developed preeclampsia, which was statistically  significant 
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 Urine  calcium – creatinine ratio at less than or equal to 0.04 showed these 
statistical results-  p value  was <0.001, Sensitivity- was 73.1%,Specificity 
was 97.7% ,Positive predictive value was 82.6%, Negative  predictive value-
96% and Statistical  accuracy of 94.5% 
 
 Urine microalbumin at 30 – 300 mg showed these statistical results-  p value  
was <0.001, Sensitivity was 61.5%,Specificity was 85% ,Positive predictive 
value was 38.1%, Negative  predictive value-93.7% and Statistical  accuracy 
of 82% 
 
 Predictive value of urine calcium – creatinine ratio w using area under curve  
of ROC  showed  that UCCR at less than or equal to 0.04 was a good test. 
 
 Predictive value of microalbuminuria  using area under curve of ROC 
showed that it was  a fair test  
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CONCLUSION 
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CONCLUSION 
Screening test for preeclampsia is very essential to prevent complications of 
preeclampsia, which is a major cause for maternal and fetal mortality and 
morbidity. There has been a constant research to find an effective screening test for 
prediction and prevention of preeclampsia, which would give a idea to implement 
measures of primary prevention. 
In past few decades number of clinical and biochemical methods for screening 
preeclampsia have been developed. However, they cannot be used as screening test 
because of their false positive results and subjective interpretation. Hence there is 
immense need for validated test for identifying pregnant women who are at risk for 
development of pre-eclampsia 
  In our present study of asymptomatic pregnant women  between 20 – 24 weeks 
gestation ,estimation of calcium – creatinine ratio at less than or equal to 0.04 in a 
spot urine sample was found to be a good  test for predicting preeclampsia .It is 
also cost effective and can be used as a screening test for pregnant women. 
Estimation of urine microalbumin in a spot sample was a fair test for predicting 
preeclampsia. It is also not cost effective .As of present situation; using urine 
microalbumin alone cannot be used as screening test. Many more trials are needed 
to recommend it as a screening test.  
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PROFORMA 
Name  
Age                                                                                          OP No.  
LMP:       
 Date of visit:  
Obstetric Formula: 
Complaints:   
Menstrual History:   R / IR 
Obstetric History: 
 
S.No. Sex Age GA at 
Birth 
Mode of 
Delivery 
Birth wt Interval 
       
 
       
 
PAST HISTORY: 
FAMILY HISTORY: 
GENARAL EXAMINATION: 
Pallor   Temp   Edema  Breast 
HT   Pulse   CVS   Thyroid: 
PER ABDOMINAL EXAMINATION: 
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INVESTIGATIONS: 
HB 
PCV 
VDRL 
BT , CT 
BLOOD SUGAR 
BLOOD GROUP 
BLOOD UREA 
SERUM CREATININE 
URINE – ALBUMIN 
    SUGAR 
    MICROSCOPY 
URINARY CALCIUM 
URINARY CREATININE 
URINE CALCIUM/CREATININE RATIO 
 
USG 
Follow up: 
At TERM – BP 
MODE OF DELIVERY 
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Date Gestation 
age 
BP Urine 
albumin 
By dipstic 
S/S of 
Imminent 
eclampsia 
Urine calcium-
creatinine ratio 
Urine 
microalbumin 
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MASTER CHART 
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        Obstetric Urine Urine    Urine    Onset of  
Sl no Name  Age 
O.P. 
No  code 
 
Calcium Creatinine Urine 
Micro 
Albumin Outcome Preelampsia at 
          (mg/dl) (mg/dl)  CCR (mg/lit)    Gestation Age 
1 NANDHINI 18 7093 primi 5.1 54 0.0944 79   (weeks) 
2 LAKSHMI 24 10477 primi 6.3 107 0.0589 10     
3 GIRIJA 20 19220 primi 8.2 145 0.0566 85     
4 NAGARANI 22 19234 G3P2L2 5.4 218 0.0248 243 
Developed 
Preeclampsia 37 
5 LAKSHMI 28 15261 G2P1L1 2.8 96 0.0292 68 
Developed 
Preeclampsia 38 
6 VINODHINI 19 19248 primi 4 66 0.0606 5     
7 PAPITHA 19 19256 primi 3.6 30 0.1200 13 
Developed 
Preeclampsia 38 
8 PREMA 27 19257 G2P1L1 2 92 0.0217 15 
Developed 
Preeclampsia 37 
9 HARITHA 20 14107 primi 8 14 0.5714 6     
10 SELVI 22 4505 primi 5 118 0.0424 28     
11 SUGANYA 21 15663 primi 12 110 0.1091 9.7     
12 LATHA 30 19935 G2P1L1 30 260 0.1154 25     
13 MALLIGA 35 18384 G2P1L1 16.8 78 0.2154 23.5     
14 LATHA 27 5982 G2P1L1 17.5 220 0.0795 25     
15 NADHIYA 25 20079 primi 6.3 84 0.0750 2.5     
16 ANITHA 30 15143 G2P1L1 3.9 112 0.0348 35 
Developed 
Preeclampsia 38 
17 MANJUMARANI 22 9966 G2A1 14.8 165 0.0897 11.7     
18 BHAGIYAM 28 17812 primi 13.3 197 0.0675 11.9     
19 SELVARANI 25 20139 G2A1 19 157 0.1210 11.9     
20 SHEELA 20 20164 primi 12.3 151 0.0815 40     
21 NOORJAHAN 20 22882 primi 3.5 38 0.0921 13.3 
Developed 
Preeclampsia 37 
22 GOMATHI 24 20299 primi 24 220 0.1091 55     
23 MANJULA 29 20318 primi 7 58 0.1207 24     
24 MEGALA 26 20305 G4P1L1A2 17 86 0.1977 3.5     
25 
VASANTHA 
KUMARI 20 16293 primi 4.2 95 0.0442 33     
26 DIVYA 26 17070 primi 19.4 245 0.0792 22     
27 REENA 20 20495 primi 10.1 62 0.1629 17.1     
28 TAMILSELVI 22 6750 G2A1 12.9 110 0.1173 41 
 
  
29 PONNI 24 18210 G3P2L1 3.9 170 0.0229 17 
Developed 
Preeclampsia 38 
30 SEETHA 22 16548 primi 4 95 0.0421 4     
31 SARALA 20 11038 primi 3.5 108 0.0324 53 
Developed 
Preeclampsia 37 
32 KAVITHA 30 12623 G2P1L1 14.5 180 0.0806 27     
33 SUGANYA 21 24341 G2P1L1 5.6 105 0.0533 65     
34 RAMYA 20 24234 primi 6.7 75 0.0893 23     
35 KOMALA 28 26527 G2P1L1 8.6 140 0.0614 29     
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36 NITHYAKALYANI 23 29310 primi 5 275 0.0182 56 
Developed 
Preeclampsia 37 
37 INDHUMATHI 19 29779 primi 14.3 140 0.1021 2.3     
38 GIRIJA 21 28857 primi 45 197 0.2284 6.5     
39 KAVITHA 25 27182 G2P1L1 10.8 60 0.1800 107     
40 SUMATHI 24 30189 primi 6.9 45 0.1533 22     
41 LAVANYA 20 22731 primi 8.5 180 0.0472 28.6     
42 PRIYA 23 14752 primi 14.9 142 0.1049 24     
43 SRIDEVI 20 17210 primi 14 65 0.2154 28     
44 MENAKA 22 29210 G2P1L1 12 95 0.1263 15.4     
45 SENDHAMARAI 27 19978 G2P1L1 6.5 240 0.0271 36.8 
Developed 
Preeclampsia 38 
46 SIVAGAMI 19 22733 primi 12 216 0.0556 20     
47 THENMOZHI 20 15715 primi 15 153 0.0980 18     
48 VEDHAVALLI 20 11875 primi 6 188 0.0319 40 
Developed 
Preeclampsia 36 
49 PREMA 22 22397 primi 6.9 30 0.2300 26     
50 HARIPRIYA 20 15718 G2P1L1 4 50 0.0800 23     
51 BANU 20 15675 primi 7.1 125 0.0568 10.3     
52 DHANALAKSHMI 23 15569 primi 5 75 0.0667 13.7 
Developed 
Preeclampsia 36 
53 JANAKI 28 22988 G3P2L2 25 40 0.6250 13     
54 AMULU 26 24123 primi 38 65 0.5846 16.7     
55 SARITHA 21 20153 primi 2.4 90 0.0267 32 
Developed 
Preeclampsia 37 
56 LAKSHMI 27 21644 primi 8 150 0.0533 12.8     
57 SAIRABEGAM 23 22737 primi 11 135 0.0815 9.6     
58 NALINI 23 30567 primi 18 125 0.1440 62     
59 SANGEETHA 26 15601 G4P1L1A2 12.5 30 0.4167 47     
60 MAHALAKSHMI 30 15587 G2P1L1 6 25 0.2400 8.7     
61 KAVITHA 25 15584 G2P1L1 7.6 60 0.1267 2.8     
62 KASTHURI 22 15127 primi 10 40 0.2500 3.1     
63 THULASI 20 15697 primi 6.5 50 0.1300 17.8     
64 SHAKIRA BEGAM 21 15566 primi 7 45 0.1556 11.7     
65 MALATHI 30 22989 G2P1L1 5.1 55 0.0927 110     
66 UMA 27 22663 G2P1L1 5.6 60 0.0933 13.5     
67 NIRMALA 25 22994 primi 4.8 35 0.1371 91     
68 BRINDHA 26 23655 G2P1L1 6.4 45 0.1422 79     
69 LALITHA 24 22971 primi 5.5 155 0.0355 85 
Developed 
Preeclampsia 38 
70 SHARMILA 29 23656 primi 10.5 162 0.0648 28     
71 DURGA 23 23670 G2P1L1 15.2 185 0.0822 26     
72 YASMIN 21 25628 primi 14.5 190 0.0763 12     
73 PRIYA 20 25732 primi 10.9 172 0.0634 28     
74 SHUBASHINI 23 25623 primi 16 175 0.0914 23.4     
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75 DIVYA 22 25607 primi 18.2 188 0.0968 12     
76 SUGANYA 20 19076 primi 20 187 0.1070 10.6     
77 UMA 20 23667 primi 17.6 200 0.0880 20     
78 THOOYARASI 36 23662 primi 13.1 215 0.0609 25.5     
79 JAYANTHI 39 22684 G2P1L1 14.8 186 0.0796 18     
80 SOWMIYA 20 21652 primi 11.8 174 0.0678 13     
81 NIRMALA DEVI 32 14568 G2P1L1 12 196 0.0612 10     
82 SEETHA 32 16548 primi 5.2 160 0.0325 32 
Developed 
Preeclampsia 37 
83 
SHANTHA 
KUMARI 23 24302 primi 15.5 176 0.0881 34     
84 AMUDHA 25 13463 G2P1L1 14.2 198 0.0717 29     
85 THASLIM BANU 20 24301 primi 7.6 78 0.0974 23     
86 SHANTHI 28 19923 G2P1L1 8.4 96 0.0875 12     
87 NARMADHA 22 18622 G3P1L1A1 6.7 86 0.0779 15.5     
88 SUDHA 26 15138 primi 4.8 37 0.1297 22     
89 BHARATHI 21 17351 G2P1L1 5.5 82 0.0671 14     
90 DURGA DEVI 22 14233 primi 8 40 0.2000 6     
91 RAJERMUNISHA  21 19761 G2P1L1 6.2 80 0.0775 8.4 
Developed 
Preeclampsia 37 
92 DHANALAKSHMI 26 17984 primi 4.5 165 0.0273 9.2 
Developed 
Preeclampsia 36 
93 FAMIDHA 26 22326 primi 4.8 170 0.0282 25     
94 RAJESHWARI 28 14916 G2A1 7.6 82 0.0927 28     
95 MUTHAMMA 25 19804 G2P1L0 14.2 182 0.0780 29     
96 SHALINI 24 12661 G3A2 12 186 0.0645 29.5     
97 TAMILSELVI 31 13190 G3P1L1A1 14.4 198 0.0727 9.1     
98 VIJAYA 20 13196 primi 6.5 165 0.0394 31 
Developed 
Preeclampsia 38 
99 
UMA 
MAHESWARI 24 13761 primi 4.8 156 0.0308 75 
Developed 
Preeclampsia 39 
100 JEEVITHA 20 10741 G2P1L1 7.2 96 0.0750 12     
101 KANNAGI 20 12024 primi 12 154 0.0779 8.6     
102 REVATHI 26 10701 G3P2L2 6.9 126 0.0548 2     
103 GEETHA 33 13798 primi 10.5 115 0.0913 10     
104 JOYCE 25 13825 primi 5.6 120 0.0467 12.5 
Developed 
Preeclampsia 37 
105 RADHA 26 13867 primi 12 126 0.0952 14     
106 RAMYA 23 13852 primi 6.2 86 0.0721 22     
107 VANISHREE 20 13837 primi 19 150 0.1267 29.8     
108 PUSHPA 28 9887 primi 24 226 0.1062 11.7     
109 NOORJAHAN 18 10628 primi 10.5 65 0.1615 11.8     
110 JAYANTHI 21 11656 primi 13 110 0.1182 12.6     
111 THENMOZHI 26 15099 primi 14.1 105 0.1343 17.4     
112 RENUKA 27 15101 G2P1L1 9.6 186 0.0516 18.9     
113 HEMAVATHI 21 13160 primi 6.4 108 0.0593 9.6     
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114 PREMALATHA 23 15123 primi 8.8 40 0.2200 21     
115 ASHKASIBEGAM 28 13781 primi 6.2 174 0.0356 26     
116 GEETHA 33 13789 primi 10.5 210 0.0500 25     
117 SHUBASHINI 31 15131 primi 14.2 115 0.1235 26     
118 DURGA DEVI 22 14233 primi 6.5 90 0.0722 28     
119 GAYATHRI 20 21279 primi 8.2 66 0.1242 29     
120 SHYAMALA 23 15344 primi 15 181 0.0829 27.7     
121 SABEENA 22 15351 primi 14 196 0.0714 9.2     
122 VIJAYA LAKSHMI 23 16173 primi 14.3 152 0.0941 7.4     
123 RATHNA 23 20159 G2P1L0 25.6 220 0.1164 6     
124 CHITRALEKA 21 15147 G3P1L1A1 15.9 250 0.0636 20     
125 
UMA 
MAHESWARI 20 22974 G2A1 16.5 200 0.0825 11     
126 LALITHA 24 23019 G2P1L1 12 196 0.0612 13.5     
127 SHENBAGAM 24 19817 G2P1L1 10 160 0.0625 24     
128 ZAHIDA BEGUM 23 16869 primi 6.4 172 0.0372 126 
Developed 
Preeclampsia 37 
129 JAMILA 28 24145 G3P1L1A1 10 160 0.0625 4     
130 HELEN MARY 20 21039 G3A2 14.6 182 0.0802 18     
131 DEVI 27 24718 G2P1L1 26 118 0.2203 23     
132 KALAIVANI 25 28235 primi 18 220 0.0818 25     
133 NANDHINI 18 23833 primi 16.4 235 0.0698 5     
134 VENMADHI 22 28290 primi 18.1 190 0.0953 4.5     
135 RENUKA 27 27724 G3P2L2 12.2 172 0.0709 20     
136 SARASWATHI 20 16031 primi 14.5 162 0.0895 10.5     
137 BHARATHI 21 20632 G2P1L1 15 186 0.0806 12.4     
138 SUGANYA 20 21782 primi 12 180 0.0667 17.6     
139 ESHA 23 14773 primi 14 165 0.0848 20     
140 MANONMANI 25 16846 G2P1L1 5.2 180 0.0289 26.7     
141 DHANALAKSHMI 26 22510 primi 6.5 105 0.0619 26     
142 SALOMI 23 10241 G3P2L2 8.6 150 0.0573 28     
143 MAHESWARI 30 18410 primi 13 110 0.1182 12     
144 VANITHA 20 15004 primi 16.8 80 0.2100 14.3     
145 PARVATHI 34 15954 G3P1L1A1 20 162 0.1235 11.7     
146 HEMALATHA 21 25466 primi 3.3 38 0.0868 11.7 
Developed 
Preeclampsia 38 
147 VIMALA 29 27050 primi 12 152 0.0789 21.8     
148 NANDHINI 19 18406 primi 18.8 152 0.1237 29     
149 RAMYA VANI 18 16849 primi 4.2 190 0.0221 189 
Developed 
Preeclampsia 35 
150 KUTTIYAMMAL 20 25127 primi 12 115 0.1043 28     
151 PAVITHRA 24 15123 primi 8.3 6.7 1.2388 11.9     
152 RADHIKA 23 20156 primi 11.5 210 0.0548 10.7     
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153 LAKSHMI 28 24633 primi 6.2 90 0.0689 9     
154 RAJESHWARI 24 27301 primi 24 210 0.1143 3     
155 
SYED ALI 
FATHIMA 26 18550 G2P1L1 15.4 211 0.0730 3.3     
156 LAKSHMI 28 15201 G4P2L2A1 7.5 92 0.0815 2.5     
157 
VENKATA 
LAKSHMI 28 26571 primi 8.2 94 0.0872 4.9     
158 VASANTHI 27 24688 G3P2L2 7.2 84 0.0857 28     
159 JAYANTHI 20 24711 primi 6.7 96 0.0698 18     
160 NIRMALA 22 18331 primi 9.2 220 0.0418 19.2     
161 MUSTAN BEE 30 18243 G2P1L1 13.7 125 0.1096 6.7     
162 VALARMATHI 20 23485 primi 3.8 45 0.0844 141     
163 SARASWATHI 30 19928 G2P1L1 2.5 55 0.0455 25 
Developed 
Preeclampsia 37 
164 SANKARI 23 18370 G2P1L1 1.9 50 0.0380 3     
165 SARITHA 27 10135 G3A2 17.5 55 0.3182 32     
166 RAJESWARI 20 23533 primi 13.5 105 0.1286 16.4     
167 SONI 22 23637 primi 10 190 0.0526 6.9     
168 SUBHALAKSHMI 21 10487 G2P1L1 9.2 50 0.1840 6     
169 JAYANTHI 20 21069 primi 10.7 195 0.0549 171     
170 GUNASUNDARI 23 6793 G2P1L1 9.5 29 0.3276 1     
171 SUSHEELA 35 21128 primi 11.8 215 0.0549 1.2     
172 JAYESHREE 25 13742 G2P1L1 5.6 355 0.0158 75 
Developed 
Preeclampsia 35 
173 POORNIMA 24 21141 G2P1L1 8.1 190 0.0426 26.3     
174 CHITHRA 22 23385 G2P1L1 10.2 120 0.0850 3.8     
175 KANIMOZHI 29 12861 primi 11.7 330 0.0355 160 
Developed 
Preeclampsia 36 
176 SUGANYA 20 21612 primi 7.2 35 0.2057 124     
177 ABDUL BEEVI 22 15726 G2P1L1 5.9 100 0.0590 79.1     
178 PRIYA 30 23661 primi 11.6 120 0.0967 70     
179 SOWMIYA 20 24354 primi 5.5 75 0.0733 14.3     
180 BENITHA JENIFER 21 19936 G2A1 17.1 105 0.1629 33     
181 LAKSHMI 24 19460 primi 8.2 30 0.2733 29     
182 PADMAVATHI 29 22776 primi 13.4 100 0.1340 38     
183 BARKATHBANU 19 14311 primi 12.2 236 0.0517 18     
184 SHANTHI 26 8845 primi 8.4 30 0.2800 14     
185 SHERIN BANU 19 23811 primi 9.5 30 0.3167 2.9     
186 SUJATHA 28 19917 primi 7.1 87 0.0816 14     
187 RAMYA 23 18466 primi 12.3 145 0.0848 10.3     
188 PRAVEENA 21 15029 primi 7.1 80 0.0888 72     
189 KOKILA 25 20960 G3A2 7.7 123 0.0626 51     
190 ESHWARI 27 16038 primi 14.1 138 0.1022 52     
191 ILAKKIYA 19 24223 primi 11.7 62 0.1887 49     
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192 MAHALAKSHMI 25 6960 G2P1L1 8.4 42 0.2000 24     
193 DEVIKA 23 11982 primi 14.9 112 0.1330 12.6     
194 AYESHYA 24 13931 G2P1L0 11.2 196 0.0571 11.9     
195 JAYAMALA 23 11986 G2P1L1 12.5 142 0.0880 25.6     
196 BHAVANI 23 11452 G2P1L1 8.6 92 0.0935 28     
197 MALA 31 8850 G2P1L1 7.8 45 0.1733 26.4     
198 VAISHNAVI 19 12655 primi 8.2 30 0.2733 29     
199 BANUPRIYA 22 20953 G2P1L1 12.6 152 0.0829 22     
200 SRIVIDYA 22 22172 G2P1L1 11.5 172 0.0669 10.5     
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ABBREVIATIONS 
ACOG American College of Obstetrics and Gynaecology 
BMI Body Mass Index 
BP Blood Pressure 
ET Endothelin 
NHBEP National High Blood Pressure Education Program 
NO Nitric Oxide 
OCPC Ortho Cresolpthaleincomplexone  reaction 
PTH Parathyroid Harmone 
p value Probability value 
PlGF Placental Growth Factor 
SFlT Soluble FMS like Tyrosine kinase 
S eng Soluble endoglin 
VEGF Vascular Endothelial Growth Factor 
UCCR  Urine Calcium Creatinine  Ratio 
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